The polypill in cardiovascular prevention: evidence, limitations and perspective - position paper of the European Society of Hypertension.

: Antihypertensive, lipid lowering, antidiabetic and antiplatelet treatments all substantially reduce the risk of cardiovascular morbid and fatal events. In real life, however, effective implementation of these treatments is rare, and thus their contribution to cardiovascular prevention is much less than it could be, based on research data. This article reviews the pros and cons of cardiovascular prevention by the polypill approach. It is argued that the high prevalence of individuals with a multifactorial risk profile provides a strong rationale for a therapeutic strategy based on the combination in a single tablet of drugs against different risk factors. It is further argued that other important favourable arguments exist. First, in real-life adherence to all above treatments is very low, leading to a major increase in the incidence and risk of cardiovascular outcomes. Second, although a large number of factors are involved, adherence is adversely affected by the complexity of the prescribed treatment regimen and can be considerably improved by treatment simplification. Third, recent studies in patients with a history of manifest cardiovascular disease have documented that different cardiovascular drugs can be combined in a single tablet with no loss of their individual efficacy or unexpected inconveniences and this does favour adherence to treatment and multiple risk factor control, supporting use of the polypill in secondary cardiovascular prevention. It is finally also mentioned, however, that the polypill may have some drawbacks and that at present no evidence is available that this approach reduces cardiovascular outcome to a greater degree than standard treatment strategies. Trials are under way to provide an answer to this question and thus allow the therapeutic value of this approach to be known.

[1]  Mark D. Huffman,et al.  Uses of polypills for cardiovascular disease and evidence to date , 2017, The Lancet.

[2]  J. Castellano,et al.  Putting polypills into practice: challenges and lessons learned , 2017, The Lancet.

[3]  G. Mancia,et al.  Blood pressure control in hypertension. Pros and cons of available treatment strategies. , 2017, Journal of hypertension.

[4]  D. Berbiche,et al.  Impact of Mental Disorders on the Association Between Adherence to Antihypertensive Agents and All‐Cause Healthcare Costs , 2017, Journal of clinical hypertension.

[5]  P. Muntner,et al.  Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012 , 2016, Hypertension.

[6]  P. Gill,et al.  Poor adherence to antihypertensive drugs , 2016, British Medical Journal.

[7]  M. Woodward,et al.  Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes , 2016, Journal of hypertension.

[8]  G. Hillis,et al.  Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease , 2016, European journal of preventive cardiology.

[9]  V. Fuster,et al.  The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. , 2015, International journal of cardiology.

[10]  V. Fuster,et al.  The cardiovascular polypill: clinical data and ongoing studies. , 2015, International journal of cardiology.

[11]  G. Mancia,et al.  Antihypertensive Medications, Loop Diuretics, and Risk of Hip Fracture in the Elderly: A Population-Based Cohort Study of 81,617 Italian Patients Newly Treated Between 2005 and 2009 , 2015, Drugs & Aging.

[12]  G. Mancia,et al.  Adherence With Antihypertensive Drug Therapy and the Risk of Heart Failure in Clinical Practice , 2015, Hypertension.

[13]  Samantha J. Togni,et al.  A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk , 2015, European journal of preventive cardiology.

[14]  G. Parati,et al.  Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. , 2015, Circulation research.

[15]  K. Rahimi,et al.  Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. , 2015, JAMA.

[16]  G. Mancia,et al.  Similarity between generic and brand‐name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population‐based study , 2014, European journal of clinical investigation.

[17]  G. Mancia,et al.  Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. , 2014, European journal of internal medicine.

[18]  V. Fuster,et al.  A polypill strategy to improve adherence: results from the FOCUS project. , 2014, Journal of the American College of Cardiology.

[19]  G. Mancia,et al.  Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data , 2014, Journal of hypertension.

[20]  G. Mancia,et al.  Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study , 2014, Diabetes Care.

[21]  R. Doughty,et al.  Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care , 2014, BMJ : British Medical Journal.

[22]  Chien‐Hua Huang,et al.  Bidirectional Adherence Changes and Associated Factors in Patients Switched From Free Combinations to Equivalent Single-Pill Combinations of Antihypertensive Drugs , 2014, Hypertension.

[23]  Hassan Khan,et al.  Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.

[24]  G. Mancia,et al.  Long-term use of statins reduces the risk of hospitalization for dementia. , 2013, Atherosclerosis.

[25]  G. Mancia,et al.  Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study , 2013, Journal of hypertension.

[26]  D. Prabhakaran,et al.  Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. , 2013, JAMA.

[27]  Claire Buckley,et al.  The Effect of Copayments for Prescriptions on Adherence to Prescription Medicines in Publicly Insured Populations; A Systematic Review and Meta-Analysis , 2013, PloS one.

[28]  A. D. Dei Tos,et al.  Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience , 2013, Expert opinion on investigational drugs.

[29]  J. Hanlon,et al.  Ethnic Disparities in Adherence to Antihypertensive Medications of Medicare Part D Beneficiaries , 2012, Journal of the American Geriatrics Society.

[30]  S. Yusuf,et al.  Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators , 2012, Circulation. Cardiovascular quality and outcomes.

[31]  T. Brennan,et al.  Full coverage for preventive medications after myocardial infarction. , 2011, The New England journal of medicine.

[32]  G. Mancia,et al.  Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice , 2011, Hypertension.

[33]  Eliseo Guallar,et al.  Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study , 2011, European heart journal.

[34]  G. Mancia,et al.  Better compliance to antihypertensive medications reduces cardiovascular risk , 2011, Journal of hypertension.

[35]  G. Mancia,et al.  Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. , 2010, Clinical therapeutics.

[36]  N. Poulter,et al.  Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis , 2010, Hypertension.

[37]  Alessandro Filippi,et al.  Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients , 2009, Circulation.

[38]  G. Mancia,et al.  Management of antihypertensive drugs in three European countries , 2009, Journal of hypertension.

[39]  A. Zanchetti Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? , 2009, Journal of hypertension.

[40]  John S. Rumsfeld,et al.  Medication Adherence: Its Importance in Cardiovascular Outcomes , 2009, Circulation.

[41]  N. Lunet,et al.  Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries , 2009, Journal of hypertension.

[42]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[43]  A. Guglietta,et al.  Issues to consider in the pharmaceutical development of a cardiovascular polypill , 2009, Nature Clinical Practice Cardiovascular Medicine.

[44]  V. Fuster,et al.  Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population , 2009, Nature Clinical Practice Cardiovascular Medicine.

[45]  R. Collins,et al.  Statins and diabetes – Authors' reply , 2008, The Lancet.

[46]  John Urquhart,et al.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories , 2008, BMJ : British Medical Journal.

[47]  G. Mancia,et al.  Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy , 2008, Journal of hypertension.

[48]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[49]  R. Herings,et al.  The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke , 2008, Current medical research and opinion.

[50]  S. Bangalore,et al.  Fixed-dose combinations improve medication compliance: a meta-analysis. , 2007, The American journal of medicine.

[51]  G. Mancia,et al.  Blood pressure control in Italy: results of recent surveys on hypertension , 2007, Journal of hypertension.

[52]  O. Shoheiber,et al.  Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[53]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension , 2007, Blood pressure.

[54]  T. Beebe,et al.  Comparison of two within-household selection methods in a telephone survey of substance abuse and dependence. , 2007, Annals of epidemiology.

[55]  V. Fuster,et al.  A polypill for secondary prevention: time to move from intellectual debate to action , 2007, Nature Clinical Practice Cardiovascular Medicine.

[56]  R. Souhami,et al.  Governance of research that uses identifiable personal data , 2006, BMJ : British Medical Journal.

[57]  B. Nightengale,et al.  Relationship of Blood Pressure Control to Adherence With Antihypertensive Monotherapy in 13 Managed Care Organizations , 2006, Journal of managed care pharmacy : JMCP.

[58]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[59]  A. de Boer,et al.  Rate and determinants of 10-year persistence with antihypertensive drugs , 2005, Journal of hypertension.

[60]  L. Mantovani,et al.  Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care , 2005, Journal of hypertension.

[61]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[62]  G. Mancia,et al.  Relationship of Office, Home, and Ambulatory Blood Pressure to Blood Glucose and Lipid Variables in the PAMELA Population , 2005, Hypertension.

[63]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[64]  D. Battleman,et al.  Predictors of adherence with antihypertensive and lipid-lowering therapy. , 2005, Archives of internal medicine.

[65]  M. Dimatteo Variations in Patients’ Adherence to Medical Recommendations: A Quantitative Review of 50 Years of Research , 2004, Medical care.

[66]  F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[67]  N J Wald,et al.  A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.

[68]  A. Rudnicka,et al.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[69]  N J Wald,et al.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.

[70]  G. Mensah,et al.  Serum Total Cholesterol Concentrations and Awareness, Treatment, and Control of Hypercholesterolemia Among US Adults: Findings From the National Health and Nutrition Examination Survey, 1999 to 2000 , 2003, Circulation.

[71]  W. Elliott Is fixed combination therapy appropriate for initial hypertension treatment? , 2002, Current hypertension reports.

[72]  J. Tu,et al.  Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes , 2002 .

[73]  S. Yusuf Two decades of progress in preventing vascular disease , 2002, The Lancet.

[74]  P. Whelton,et al.  The Impact of JNC-VI Guidelines on Treatment Recommendations in the US Population , 2002, Hypertension.

[75]  R. Düsing,et al.  Adverse events, compliance, and changes in therapy , 2001, Current hypertension reports.

[76]  J Urquhart,et al.  Some economic consequences of noncompliance , 2001, Current hypertension reports.

[77]  J. Cramer,et al.  A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.

[78]  L. Guize,et al.  Cardiovascular Mortality in Hypertensive Men According to Presence of Associated Risk Factors , 2001, Hypertension.

[79]  D. Wood,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.

[80]  A. Zanchetti,et al.  Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy , 2000, Journal of hypertension.

[81]  L. Vaur,et al.  Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial. , 1999, American journal of hypertension.

[82]  A. Mcguire,et al.  The direct costs to the NHS of discontinuing and switching prescriptions for hypertension , 1998, Journal of Human Hypertension.

[83]  T. Akera,et al.  The impact of side effects on hypertension management: a Japanese survey. , 1997, Clinical therapeutics.

[84]  R. Säljö,et al.  Taking antihypertensive medication--controlling or co-operating with patients? , 1995, International journal of cardiology.

[85]  J. Mccombs,et al.  The Costs of Interrupting Antihypertensive Drug Therapy in a Medicaid Population , 1994, Medical care.

[86]  S. Bangalore,et al.  Good news from Lake Wobegon. , 2006, The American journal of medicine.

[87]  W. Kannel,et al.  Risk stratification in hypertension: new insights from the Framingham Study. , 2000, American journal of hypertension.